Trends in antihyperglycemic medication prescriptions and hypoglycemia in older adults: 2002-2013

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Clemens, Kristin K ^a   Shariff, Salimah ^b   Liu, Kuan ^b   Hramiak, Irene ^a   Mahon, Jeffrey L ^a   McArthur, Eric ^b   Garg, Amit X ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DEMENTIA; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEOPLASM; NEUROPATHY; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; POPULATION RESEARCH; PRESCRIPTION; RETINOPATHY; TRANSIENT ISCHEMIC ATTACK; TREND STUDY; VERY ELDERLY; CHEMICALLY INDUCED; CLINICAL PRACTICE; PREVALENCE; TRENDS;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE;

EID: 84947804744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137596     Document Type: Article

References (34)

1. Rathmann W, Haastert B, Icks A, Giani G. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004. Diabetes Care. 2007; 30:848-53. PMID: 17392545
2. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997; 50:735-41. PMID: 9250272
3. Doucet J, Chacra A, Maheux P, Lu J, Harris S, Rosenstock J. Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus. Curr Med Res Opin. 2011; 27:863-9. doi: 10.1185/03007995. 2011.554532 PMID: 21323504
4. Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: A prospective, double-blind, randomized, 1-year study. Diabetes, Obes Metab. 2013; 15:906-14.
5. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545-59. doi: 10.1056/NEJMoa0802743 PMID: 18539917
6. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358:2560-72. doi: 10.1056/NEJMoa0802987 PMID: 18539916
7. Statistics Canada website. Statistics Canada: Population by sex and age group, by province and territory (Number, both sexes). 2014. Available: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo31a-eng.htm
8. Bronskill S. Aging in Ontario: An ICES Chartbook of Health Service Use by Older Adults [Internet]. Insitute for Clinical Evaluative Sciences. 2010. Available: https://www.oanhss.org/oanhssdocs/Issue-Positions/External-Resources/AAH-Chartbook-interactive-final-2010.pdf
9. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61:344-9. doi: 10.1016/j.jclinepi.2007.11.008 PMID: 18313558
10. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: Determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002; 25:512-6. PMID: 11874939
11. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003; 10:67-71. PMID: 12879144
12. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352:854-65. PMID: 9742977
13. Harper W. Canadian Diabetes Association Guidelines: Pharmacological Management of Type 2 Diabetes [Internet]. Canadian Diabetes Association. 2013. Available from: http://guidelines.diabetes.ca/Browse/Chapter13
14. Zaharan NL, Williams D, Bennett K. Prescribing of antidiabetic therapies in Ireland: 10-Year trends 2003-2012. Ir J Med Sci. 2014; 183:311-8. doi: 10.1007/s11845-013-1011-1 PMID: 24013870
15. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Trends in the prescription of anti-diabetic medications in the United Kingdom: A population-based analysis. Pharmacoepidemiol Drug Saf. 2009; 18:973-6. doi: 10.1002/pds.1802 PMID: 19621344
16. Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract [Internet]. 2011 Jul [cited 2014 Sep 29]; 93(1):123-30. Available from: http://www.sciencedirect.com/science/article/pii/S0168822711002312
17. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003-2012. Diabetes Care. 2014; 37:1367-74. doi: 10.2337/dc13-2289 PMID: 24623020
18. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, et al. Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost Implications. The American Journal of Medicine. 2012. p. 302.e1-302.e7.
19. Meinelly G. Canadian Diabetes Association Guidelines: Diabetes in the Elderly [Internet]. Canadian Diabetes Association. 2013. Available: http://guidelines.diabetes.ca/Browse/Chapter37
20. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008; 31:845-51. doi: 10.2337/dc07-2270 PMID: 18223031
21. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010; 170:1191-201. doi: 10.1001/archinternmed.2010.207 PMID: 20656674
22. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009; 373:2125-35. doi: 10.1016/S0140-6736(09)60953-3 PMID: 19501900
23. Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA [Internet]. 2007 Dec 12 [cited 2015 Mar 5]; 298(22):2634-43. Available from: http://www.ncbi.nlm.nih.gov/Pub Med/18073359
24. Hashim S, Gomes T, Juurlink D, Hellings C, Mamdani M. The rise and fall of the thiazolidinediones: Impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones. J Popul Ther Clin Pharmacol. 2013; 20.
25. Foster PD, Mamdani MM, Juurlink DN, Shah BR, Paterson JM, Gomes T. Trends in selection and timing of first-line pharmacotherapy in older patients with type 2 diabetes diagnosed between 1994 and 2006. Diabet Med. 2013; 30:1209-13. doi: 10.1111/dme.12214 PMID: 23586333
26. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298:1180-8. PMID: 17848652
27. Cohen A, Rababni A, Shah N, Alexander G. Changes in Glitazone Use Among Office-Based Physicians in the U. S., 2003-2009. Diabetes Care. 2010; 33:2009-11.
28. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial in macro Vascular Events): A randomised controlled trial. Lancet. 2005; 366:1279-89. PMID: 16214598
29. Garber AJ, Larsen J, Schneider SH, Piper BA, Henry D. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes, Obes Metab. 2002; 4:201-8.
30. Rosenstock J, Goldstein BJ, Vinik AI, O'Neill MC, Porter LE, Heise MA, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes, Obes Metab. 2006; 8:49-57.
31. Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes, Obes Metab. 2006; 8:650-60.
32. Lipska KJ, Ross JS, Wang Y, Inzucchi SE, Minges K, Karter AJ, et al. National Trends in US Hospital Admissions for Hyperglycemia and Hypoglycemia Among Medicare Beneficiaries, 1999 to 2011. JAMA Intern Med [Internet]. 2014; 174:1116-24. Available from: http://www.ncbi.nlm.nih.gov/Pub Med/24838229
33. Booth GL, Hux JE, Fang J, Chan BTB. Time trends and geographic disparities in acute complications of diabetes in Ontario, Canada. Diabetes Care. 2005; 28:1045-50. PMID: 15855565
34. Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ. Rates of Complications and Mortality in Older Patients With Diabetes Mellitus: The Diabetes and Aging Study. JAMA Intern Med [Internet]. 2013; 60637:251-8. Available from: http://www.ncbi.nlm.nih.gov/Pub Med/24322595